Press Room

Find news and updates from PhRMA, representing the country’s leading biopharmaceutical research companies. Our members are committed to finding tomorrow’s cures and treatments for some of the most serious diseases such as cancer, Alzheimer’s disease, cystic fibrosis and Parkinson’s.

Latest News from PhRMA

PhRMA Statement on JAMA Clinical Trials Study

September 26, 2018

“This study’s narrow findings should not be used to make sweeping generalizations about the investment biopharmaceutical companies make in the development of new therapies.

Read More

Nearly 1 in 5 Hospitals Marks Up Medicine Prices at Least 700 Percent

September 5, 2018

Nearly one in five hospitals marks up medicine prices 700 percent or more, according to a new analysis from the Moran Company that was commissioned by PhRMA.

Read More

PhRMA Statement on Biosimilars Action Plan

July 18, 2018

PhRMA issued the following statement upon release of the U.S. Food and Drug Administration’s Biosimilar Action Plan.

Read More

Biopharmaceutical Industry Takes Bold New Policy Position on How Payments Should Work in Supply Chain

July 16, 2018

PhRMA announces a bold new policy position on how payments should work in the supply chain.

Read More

PhRMA Statement on Efforts to Support Real-World Evidence

July 12, 2018

PhRMA spokesperson issued a statement on comments made by U.S. FDA Commissioner Scott Gottlieb.

Read More

Nevada Addresses SB 539’s Most Significant Flaws

June 29, 2018

Judge James C. Mahan of the United States District Court for the District of Nevada entered an order yesterday dismissing without prejudice litigation brought by PhRMA and the Biotechnology Innovation Organization (BIO) against the State of Nevada.

Read More

New Analysis Shows Using ICER’s Value Assessments Would Limit Access to Life-Saving Medicines in Medicare Part B

May 31, 2018

If Medicare were to utilize one-size-fits-all value assessments like the Institute for Clinical and Economic Review’s (ICER) framework as the basis for coverage, 62 to 93 percent of patients with serious, complex conditions would face access barriers to life-saving medicines, according to a new analysis from Xcenda.

Read More

PhRMA Statement on President Trump’s Drug Pricing Blueprint

May 11, 2018

PhRMA president and CEO Stephen J. Ubl issued a statement on President Donald Trump’s drug pricing blueprint.

Read More

PhRMA Welcomes 2018 Special 301 Report

April 27, 2018

The Pharmaceutical Research and Manufacturers of America (PhRMA) welcomed the 2018 Special 301 Report, including a new section devoted to pharmaceutical market access barriers, released today by U.S. Trade Representative (USTR) Robert Lighthizer.

Read More